Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) have been given an average rating of "Hold" by the five analysts that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $15.00.

VIGL has been the topic of a number of recent research reports. Citigroup downgraded shares of Vigil Neuroscience to a "market perform" rating in a report on Thursday. JMP Securities reiterated a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday. Wedbush downgraded shares of Vigil Neuroscience from an "outperform" rating to a "neutral" rating and dropped their target price for the stock from $13.00 to $8.00 in a report on Thursday. HC Wainwright dropped their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Friday, March 14th. Finally, William Blair restated a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday.

Vigil Neuroscience Stock Up 241.1%

Shares of NASDAQ:VIGL opened at $7.88 on Friday. The firm has a fifty day moving average of $2.07 and a two-hundred day moving average of $2.27. The firm has a market capitalization of $367.78 million, a P/E ratio of -3.83 and a beta of 1.90. Vigil Neuroscience has a 12-month low of $1.31 and a 12-month high of $7.95.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. Equities research analysts expect that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC boosted its position in shares of Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after acquiring an additional 8,358 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Vigil Neuroscience during the 4th quarter valued at about $83,000. Barclays PLC boosted its position in Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares in the last quarter. Northern Trust Corp boosted its position in Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after buying an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its position in Vigil Neuroscience by 243.8% in the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock valued at $117,000 after buying an additional 49,000 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.